EA021994B1 - Антагонисты мускариновых рецепторов ацетилхолина - Google Patents

Антагонисты мускариновых рецепторов ацетилхолина Download PDF

Info

Publication number
EA021994B1
EA021994B1 EA201100019A EA201100019A EA021994B1 EA 021994 B1 EA021994 B1 EA 021994B1 EA 201100019 A EA201100019 A EA 201100019A EA 201100019 A EA201100019 A EA 201100019A EA 021994 B1 EA021994 B1 EA 021994B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
hydroxy
oxy
diphenyl
octane bromide
Prior art date
Application number
EA201100019A
Other languages
English (en)
Russian (ru)
Other versions
EA201100019A1 (ru
Inventor
Драман И. Лэн
Майкл Р. Палович
Брент У. Макклеланд
Кристофер Э. Нейпп
Соня М. Томас
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA021994(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201100019A1 publication Critical patent/EA201100019A1/ru
Publication of EA021994B1 publication Critical patent/EA021994B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
EA201100019A 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина EA021994B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27

Publications (2)

Publication Number Publication Date
EA201100019A1 EA201100019A1 (ru) 2011-12-30
EA021994B1 true EA021994B1 (ru) 2015-10-30

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100019A EA021994B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина
EA200601991A EA015033B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200601991A EA015033B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина

Country Status (38)

Country Link
US (9) US7498440B2 (enExample)
EP (3) EP3111936A1 (enExample)
JP (2) JP5014121B2 (enExample)
KR (2) KR101037026B1 (enExample)
CN (2) CN102040602A (enExample)
AP (1) AP2213A (enExample)
AR (1) AR050902A1 (enExample)
AU (1) AU2005237576B2 (enExample)
BE (1) BE2014C063I2 (enExample)
BR (1) BRPI0510170B8 (enExample)
CA (2) CA2755954C (enExample)
CY (3) CY1113196T1 (enExample)
DK (2) DK1740177T3 (enExample)
EA (2) EA021994B1 (enExample)
EC (1) ECSP066940A (enExample)
ES (2) ES2392848T4 (enExample)
FR (1) FR14C0075I2 (enExample)
HR (2) HRP20120832T1 (enExample)
HU (2) HUE031304T2 (enExample)
IL (1) IL178152A (enExample)
LT (1) LT2570128T (enExample)
LU (1) LU92565I2 (enExample)
MA (1) MA28631B1 (enExample)
MX (1) MXPA06012405A (enExample)
MY (1) MY144753A (enExample)
NL (1) NL300694I1 (enExample)
NO (3) NO338959B1 (enExample)
NZ (1) NZ549997A (enExample)
PE (1) PE20060259A1 (enExample)
PL (2) PL2570128T3 (enExample)
PT (2) PT1740177E (enExample)
SG (1) SG186597A1 (enExample)
SI (2) SI1740177T1 (enExample)
TW (1) TWI363759B (enExample)
UA (1) UA95768C2 (enExample)
UY (1) UY28871A1 (enExample)
WO (1) WO2005104745A2 (enExample)
ZA (1) ZA200608565B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
EP1677796A4 (en) * 2003-10-17 2006-12-27 Glaxo Group Ltd MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1725238A4 (en) * 2004-03-17 2009-04-01 Glaxo Group Ltd M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS
JP2007531792A (ja) * 2004-04-05 2007-11-08 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖキヌクリジン化合物
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
JP2008520579A (ja) * 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
KR20090003349A (ko) 2006-04-20 2009-01-09 글락소 그룹 리미티드 화합물
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PT2046787E (pt) 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
AR076435A1 (es) 2009-04-30 2011-06-08 Glaxo Group Ltd Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
KR101781237B1 (ko) * 2010-01-28 2017-09-22 테론 파마슈티칼즈, 인크. 7-아조니아바이시클로〔2.2.1〕헵탄 유도체, 제조 방법, 및 그의 제약적 용도
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
UA107499C2 (uk) * 2010-06-22 2015-01-12 Chiesi Farm Spa Склад сухого порошку, який містить антимускариновий засіб
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20140041700A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄을 포함하는 건조 분말 흡입기 조성물
US20140113888A1 (en) 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
WO2014027045A1 (en) 2012-08-15 2014-02-20 Glaxo Group Limited Chemical process
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
CN105431432B (zh) * 2013-07-13 2018-01-09 北京硕佰医药科技有限责任公司 奎宁类化合物、其光学异构体及其制备方法和医药用途
EA201690302A1 (ru) * 2013-07-30 2016-06-30 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Композиции для местного применения для лечения избыточного потоотделения и способы их применения
JP2016537327A (ja) 2013-10-17 2016-12-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
RU2016112266A (ru) 2013-10-17 2017-11-20 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
EP3650019B8 (en) 2014-05-28 2023-10-11 GlaxoSmithKline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
JP6615212B2 (ja) * 2014-11-03 2019-12-04 オロン ソシエタ ペル アチオニ １−（２−ハロゲン−エチル）−４−ピぺリジンカルボン酸エチルエステルの製法
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
KR102794286B1 (ko) * 2016-01-08 2025-04-09 테론 파마슈티칼즈, 인크. 7-아조니아바이사이클로[2.2.1]헵탄 유도체의 건조 분말 흡입기 조성물
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (enExample) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NL192564C (nl) 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
EP0211595B1 (en) 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
AU5790598A (en) 1996-12-02 1998-06-29 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
RU2004110717A (ru) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
US6951868B2 (en) * 2001-11-09 2005-10-04 Pfizer Inc. Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
EP1613307A4 (en) 2003-04-07 2008-03-12 Glaxo Group Ltd M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
UY28417A1 (es) 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
AR048573A1 (es) 2003-07-17 2006-05-10 Glaxo Group Ltd Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
SI1677795T1 (sl) 2003-10-14 2011-04-29 Glaxo Group Ltd Antagonisti muskarinskega acetilholinskega receptorja
EP1677796A4 (en) 2003-10-17 2006-12-27 Glaxo Group Ltd MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
PE20050897A1 (es) 2003-12-03 2005-11-06 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20070179131A1 (en) 2004-03-11 2007-08-02 Jian Jin Novel M3 Muscarinic Acetylcholine Receptor Antagonists
JP2007529512A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1725238A4 (en) 2004-03-17 2009-04-01 Glaxo Group Ltd M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS
WO2005094835A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20070238751A1 (en) 2004-04-07 2007-10-11 Laine Dramane I Muscarinic Acetylcholine Receptor Antagonists
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (en) 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
WO2005118594A1 (en) 2004-05-28 2005-12-15 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008505118A (ja) 2004-06-30 2008-02-21 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1781104A4 (en) 2004-08-05 2008-05-21 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2006017767A2 (en) 2004-08-06 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006050239A2 (en) 2004-10-29 2006-05-11 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1827439A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
JP2008520579A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
US20080275079A1 (en) 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
US20080234315A1 (en) 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEDA, K et al. M3 receptor angagonism by the novel antimuscarmic agent solifenacin in the urinary bladder and salivary gland, Naimyn-Schmiedeberg's Arch Pharmacol, 2002, vol. 366, pages 97-103, abstract *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
ES2392848T4 (es) 2014-10-01
TW200605887A (en) 2006-02-16
SI1740177T1 (sl) 2012-12-31
JP2007534769A (ja) 2007-11-29
NO2017018I1 (no) 2017-05-04
EP3111936A1 (en) 2017-01-04
AP2213A (en) 2011-03-01
US7488827B2 (en) 2009-02-10
CN102040602A (zh) 2011-05-04
CY2014043I1 (el) 2015-12-09
HRP20120832T1 (hr) 2012-11-30
DK2570128T3 (en) 2016-11-07
NL300694I2 (enExample) 2015-12-29
US8183257B2 (en) 2012-05-22
WO2005104745A2 (en) 2005-11-10
NO20065417L (no) 2006-12-29
NO338959B1 (no) 2016-11-07
LT2570128T (lt) 2016-10-10
BRPI0510170B1 (pt) 2018-12-18
PT2570128T (pt) 2016-10-07
LU92565I9 (enExample) 2019-01-17
EA200601991A1 (ru) 2007-02-27
NO2017017I1 (no) 2017-05-04
ECSP066940A (es) 2006-12-20
KR101152032B1 (ko) 2012-06-11
MA28631B1 (fr) 2007-06-01
WO2005104745A3 (en) 2006-08-03
CY1118082T1 (el) 2017-06-28
NZ549997A (en) 2010-10-29
EA015033B1 (ru) 2011-04-29
CA2564742C (en) 2012-01-10
MXPA06012405A (es) 2007-01-17
NL300694I1 (enExample) 2015-12-29
PE20060259A1 (es) 2006-03-25
US8575347B2 (en) 2013-11-05
JP5398871B2 (ja) 2014-01-29
US20140371264A1 (en) 2014-12-18
JP5014121B2 (ja) 2012-08-29
CA2564742A1 (en) 2005-11-10
FR14C0075I1 (fr) 2014-11-21
JP2012162559A (ja) 2012-08-30
ES2600405T3 (es) 2017-02-08
SI2570128T1 (sl) 2016-11-30
AU2005237576B2 (en) 2012-01-12
US7498440B2 (en) 2009-03-03
US20090124653A1 (en) 2009-05-14
TWI363759B (en) 2012-05-11
NO2017018I2 (no) 2018-05-14
AU2005237576A1 (en) 2005-11-10
PT1740177E (pt) 2012-11-02
LU92565I2 (fr) 2014-12-02
UA95768C2 (ru) 2011-09-12
UY28871A1 (es) 2005-11-30
US9144571B2 (en) 2015-09-29
MY144753A (en) 2011-10-31
ZA200608565B (en) 2019-12-18
US8309572B2 (en) 2012-11-13
CA2755954C (en) 2014-02-18
US20120157491A1 (en) 2012-06-21
EP1740177A4 (en) 2010-05-05
FR14C0075I2 (fr) 2015-05-22
EP1740177B1 (en) 2012-08-08
KR101037026B1 (ko) 2011-05-25
BRPI0510170A (pt) 2007-10-02
US20130030015A1 (en) 2013-01-31
HK1102423A1 (en) 2007-11-23
CN1976701A (zh) 2007-06-06
DK1740177T3 (da) 2012-10-29
EA201100019A1 (ru) 2011-12-30
BE2014C063I2 (enExample) 2024-08-08
CA2755954A1 (en) 2005-11-10
PL1740177T3 (pl) 2012-12-31
US9045469B2 (en) 2015-06-02
SG186597A1 (en) 2013-01-30
US8853404B2 (en) 2014-10-07
IL178152A (en) 2011-05-31
AR050902A1 (es) 2006-12-06
US20070185155A1 (en) 2007-08-09
HUS1400053I1 (hu) 2017-07-28
IL178152A0 (en) 2006-12-31
EP1740177A2 (en) 2007-01-10
HUE031304T2 (hu) 2017-07-28
HRP20161385T1 (hr) 2016-12-02
ES2392848T3 (es) 2012-12-14
CY2014043I2 (el) 2015-12-09
KR20110010841A (ko) 2011-02-07
PL2570128T3 (pl) 2017-09-29
US20150238470A1 (en) 2015-08-27
EP2570128A1 (en) 2013-03-20
AP2006003746A0 (en) 2006-10-31
EP2570128B1 (en) 2016-08-10
KR20070015412A (ko) 2007-02-02
CY1113196T1 (el) 2015-12-09
BRPI0510170B8 (pt) 2021-05-25
US20160002220A1 (en) 2016-01-07
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
CA2564742A1 (en) Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
CN1906183B (zh) N-酰基磺酰胺细胞程序死亡促进剂
KR100362620B1 (ko) 알레르기성질환치료에유용한치환된피페리딘,이를포함하는약제학적조성물및이의제조방법
JP2024532374A (ja) Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
DE60107221T2 (de) Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
EP0844877A1 (en) Use of oxido-squalene cyclase inhibitors to lower blood cholesterol
CA2084531A1 (en) Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
JP2009540013A5 (enExample)
RU2006127572A (ru) Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2003535887A5 (enExample)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2004110717A (ru) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
WO2001025228A1 (en) Amine derivatives
JP2016536333A5 (enExample)
JP2005516954A (ja) １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
FR2814678A1 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
JPWO2005097738A1 (ja) 新規スルホンアミド誘導体
BRPI0213393B1 (pt) derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
RU2006122553A (ru) Производные пиразола в качестве лекарственных средств для лечения острых или хронических дегенераций нейронов
RU2014109853A (ru) Соединения для связывания со специфическим для тромбоцитов гликопротеином iib/iiia и их применение для визуализации тромбов
EP0775138B1 (en) TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO 2,3-b]PYRIDINE
JP2005514389A (ja) タキキニンのアンタゴニストとしてのラクタム
JP2004507527A5 (enExample)
JP2009504768A5 (enExample)
AU2004218115A1 (en) Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM